I do see a subjective deal with
Wyeth and Elan for using a portion of ILNS's platform with a 50/50 development of 'Bapineuzumab' by both Wyeth and Elan. I suspect any royalties, since they're described as 'broad-based' licenses would be on the nominal side. This of course is all predicated upon favorable Phase 3 trials for Bapineuzumab, which ILNS has no ownership. This is also predicated upon an assumption that amyloid plaques are anything more than a marker for AD. This is further convoluted upon what basis this mechanism works, insofar as this patent is concerned, and whether it will ultimately lead to defensibility . Pfizer has Aricept which has been addressing brain-cell amyloid plaque for many years now, with quite limited success. This all comes full circle again to addressing a marker (amyloid plaque), rather than something more rudimentary and causative associated with AD.
In short, INLS is banking on royalties from a 'maybe' which to date hasn't been proven, and that their platform patent 'might' be unique and suitable, while more research in the AD field is leading away from these plaques.
Due to a recent serendipitous discovery while performing DBS on humans (deep brain stimulation) it was learned that memories are actually being stored in the hypothalamus region of the brain. This flies in the face of conventional brain mapping, and is causing quite a stir in neurology. This may well lead to a cannaboid drug being developed for AD yes marijuana based,(studies have already commenced) as the human endo cannabinoid system, and other indicators commonly associated with the hypothalamus region (stimulation for hunger) have long been known to emulate from there, ie- the munchies :)
I don't think INLS is cutting edge enough. They're simply following the crowd in this regard, and the crowd is following a marker, not causation, therefore, and ergo INLS is a long shot, based on another long shot based on a hypothesis, ergo not a good bet :)
Oh, and it's an OTC penny stock also, so likey scammy t'boot :)
